Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 21 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  NHLRcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm4ZY17Oi1{NfMAje69VQ>? NY[3NWxvPzJiaB?= M2rD[olvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MXiyOlE{PzFyNR?=
Tca8113/CBP  Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XrfFIuOjYkgJpOwG0> NV\BO29JPzJiaB?= M1K2SYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NHPVcVEzPjF|N{GwOS=>
Tca8113/PYM  MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTQNk0zPeLCid88US=> MYO3NkBp NWjROItpcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NUi3T|Q3OjZzM{exNFU>
SKOV3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPkeppTPjBibXevcYw> M2iyb|EuPSCm NXzycFVncW6qaXLpeJMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?= M{DMe|I3OTN5MESz
SKOV3 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrDNE01KM7:Zz;tcC=> Mo\0NlQwPDhxN{KgbC=> M3;icYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? Mo\jNlYyOjV{N{O=
SKOV3 M4Prb2Fxd3C2b4Ppd{BCe3OjeR?= MlrtNkDPxGdxbXy= NELSZWI1QCCq NIS0TZVqdmS3Y3XzJIFxd3C2b4Ppdy=> MWCyOlEzPTJ5Mx?=
OSA NXrkdJRqS2yxbn;n[Y5q[yCDc4PhfS=> NFL4emkzNjVxNTFOwG0> NHjBWJhz\XO3bITzJIlvKGyxd3XyJINwdG:weTDmc5Ju[XSrb36gZZMh[2:vcHHy[YQhfG9iZXn0bIVzKEKPSUGgd4lTVkFidILlZZRu\W62 MYmyOlEyODZ{MB?=
A549 MmXrSpVkfGmxbjDBd5NigQ>? MUOwM|I2NzVyIN88US=> NFTZ[5gzPCCq M4jvdIRwf26{ZXf1cIF1\XNibXnSMVIxPSCneIDy[ZN{cW:wwrC= NFHmNI8zPTlzN{OxOy=>
H1975 NIjFPHlHfWO2aX;uJGF{e2G7 M2XPUlAwOjVxNUCg{txO NU\NXWJxOjRiaB?= NVvGU5c5\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> Ml22NlU6OTd|MUe=
A549 MVvGeYN1cW:wIFHzd4F6 MYSwM|I2NzVyIN88US=> MWCyOEBp NYmzbJBnfXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w MXiyOVkyPzNzNx?=
H1975 NYT1VlZnTnWldHnvckBCe3OjeR?= Mn\rNE8zPS93MDFOwG0> NXPHc3JpOjRiaB?= MVz1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44> MX6yOVkyPzNzNx?=
A549 NYq1TIs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPyNlUh|ryP NX[wZoVQOjRiaB?= NFjIW5JqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MXqyOVkyPzNzNx?=
H1975 NITCRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\FNlUh|ryP NUnqT2c4OjRiaB?= MX3pcohq[mm2czDj[YxtKGe{b4f0bC=> MnPQNlU6OTd|MUe=
MDA-MB-231 Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f3dlAuOjJyIN88[{9udA>? MmX1O|IhcA>? NH[4eodKSzVywrC9JFg3KM7:TR?= MYWyOVg{PzZ7MR?=
T47D NILJVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLlNIR{OC1{MkCg{txoN22u NVj2d3IyPzJiaB?= NYXuRXJSUUN3MNMgQUA1QC57IN88US=> NGrTUpIzPTh|N{[5NS=>
LCTCC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfpTWM2OD1|LklihKnDvU1? MVOyOVc4OzF4Nx?=
MCTCC MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHnU2dKSzVyPUKuPQKBkcL3TR?= NHfPeZYzPTd5M{G2Oy=>
MegTCC NV\5NoE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrPTWM2OD12LkJihKnDvU1? M1zUN|I2Pzd|MU[3
MonoTCC NH2zdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK5V5IzUUN3ME21MlbjiIoEtV2= MUOyOVc4OzF4Nx?=
MCF7 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLoNlAh|ryP MVG3NkBp MVzpcoR2[2W|IHPlcIwh\GWjdHigc4YhUFBzzsKt[IVxdGW2ZXSgUWNHPyClZXzsdy=> NEexSoczPTd4OUCyOS=>
A-549  NWmzc2hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MViwMlUh|ryP MVmyOEBp NEL1eYFFVVORwrC= NEnDeZNqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 NX:2d4ZxOjV5NUW2PVA>
A-549  MVPBdI9xfG:|aYOgRZN{[Xl? MnzKNE42KM7:TR?= NXX1WIlmPDhiaB?= NVPzXnd{TE2VT9Mg MVzzbI94eyCnYYLsfUBieG:ydH;zbZMh\mWjdIXy[ZMhcW6lbIXkbY5oKGKuZXLibY5oKGGwZDDjbJJwdWG2aX6gZ49v\GWwc3H0bY9v NWTLPZB6OjV5NUW2PVA>
A-549  M3ryOmZ2[3Srb36gRZN{[Xl? NV;LVIdqOC53IN88US=> NX7UNlhQPDhiaB?= M4HKVmROW00EoB?= MnPZd4hwf3NiYXLldpJidnRibXnjdo91fWK3bHWg[Il{enWydHnvci=> MmWyNlU4PTV4OUC=
A-549  M1KzWGZ2[3Srb36gRZN{[Xl? M3[zdlAvPSEQvF2= MWS0PEBp NYS5XHdmTE2VT9Mg MVTpcohq[mm2czDv[kBk\WyuIH3p[5JifGmxbtMg NUC2UI92OjV5NUW2PVA>
RMG-1 NY\QcXJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJ6LkigxtEhOy54IH3nM2w> NX;EZ2tMOjV5Mk[5NVM>
FN-RMG-1 NWPtW4VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W5XGlEPTB;NECuOUDDuSB2LkKgcYcwVApizszN NFTtXIkzPTd{NkmxNy=>
RMG-1-hFUT M4nqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\XOmxyUUN3ME21PE4yKMLzIEKuOEBu\y:O M2HRXVI2PzJ4OUGz
FN-RMG-1-hFUT NE\2PI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXhUmpVUUN3ME2xNVgvQCEEsTCxN{45KG2pL1y= MluyNlU4OjZ7MUO=
CHP-134  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqxJO69VQ>? MWTEUXNQyqB? M4\Md4lvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? NEXUZYgzPTZ3OES2Ny=>
IMR-32 NH;heYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnIboUzOSEQvF2= NYnFeYc5TE2VT9Mg MYfpcohq[mm2czDzbYdvcW[rY3HueEBk\WyuIHfyc5d1cCClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> MkW1NlU3PTh2NkO=
CHP-134  NWnzNFA1TnWldHnvckBCe3OjeR?= Mlz6NVAh|ryPwrC= NHLMSYFFVVORwrC= M2DuRYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy MW[yOVY2QDR4Mx?=
IMR-32 NXrucFV7TnWldHnvckBCe3OjeR?= MWKxNEDPxE4EoB?= M3e5VGROW00EoB?= NWHMXZhmcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? MkDkNlU3PTh2NkO=
A549 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LhWVAvOi12MECwJO69VQ>? NYLrc5h2PzJiaB?= MWPJR|UxRTF{NjFCtUA2NjBizszN MoTKNlU3OjV{NEO=
A549/CDDP M2fEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[wMlIuPDByMDFOwG0> NV32VlN4PzJiaB?= NVH1NIU2UUN3ME2yOFDDqMLzwrC0OU44KM7:TR?= M{LnZ|I2PjJ3MkSz
H460  M{HtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1SyblI1KGh? MkHCSG1UVw>? NEj4foxKSzVyPUeuPUDPxE1? M{L2UVI2PTl7OUm1
H460  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M321dFcvQSEQvF2= NH7GRVQzPCCq NGCwPYNFVVOR M3fZdJNpd3e|IHGgdoFlcW:|ZX7zbZRqgmmwZzDl[oZm[3RidH:gXE1z[Xm| M2SwflI2PTl7OUm1
NRK-52E MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXyd|Y4OsLiaNMg M1nKTGlEPTB;MUCwJOKyKDF{Lkmg{txO MoDhNlU2PjV4MEO=
RGE MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33rRVczyqCqwrC= NU\r[XFYUUN3ME2yNkDDuSB5LkSg{txO MVGyOVU3PTZyMx?=
NRK-52E NITQUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3YTGpNPzMEoHlCpC=> NYLsVXdRUUN6ME2xO|khyrFiOT61JO69VQ>? MWeyOVU3PTZyMx?=
RGE MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrNPWlRPzMEoHlCpC=> NY\STYJtUUN6ME22N{DDuSB5LkSg{txO NFvJXHQzPTV4NU[wNy=>
SK-OV-3 M2TBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkewO|IhcA>? NGXkdGxKSzVyPUGwOE45KM7:TR?= NFjlWZEzPTV{MEGzNi=>
ES-2 NXzFVm1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW3NkBp MULJR|UxRTF2Lk[g{txO Mn3jNlU2OjBzM{K=
OVCAR-8 NXzTbYt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDFOVY4OiCq NIf4WWdKSzVyPUm2MlAh|ryP NELOUm4zPTV{MEGzNi=>
3AO M4LlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnGO|IhcA>? MWDJR|UxRTZ|LkSg{txO NUnJUZBkOjV3MkCxN|I>
A2780 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P3T|czKGh? M3LhW2lEPTB;MUS1Mlch|ryP NULadWZtOjV3MkCxN|I>
SW626 MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KwZVczKGh? Mm\MTWM2OD17Nz6wJO69VQ>? NInNOHEzPTV{MEGzNi=>
OVCAR-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe5O|IhcA>? NWPITGtPUUN3ME2zNk43KM7:TR?= NEThWYYzPTV{MEGzNi=>
A549 M3flVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF3MT61OkDDuSB3Mz6wOkDPxE1? MVOyOVI4PzR4MR?=
4T1 M{Hi[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj2fFlKSzVyPUi0MlYzKMLzIEOwMlA2KM7:TRqg{txO NV\GVI1FOjV{N{e0OlE>
BALB/3T3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF2LkOwJOKyKDZwNkig{txO MY[yOVI4PzR4MR?=
B16 NGrTR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{n2W2lEPTB;NkSuN|AhyrFiNj64NUDPxE1? MojFNlUzPzd2NkG=
DU 145 NFjacHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDiOoZOUUN3ME2zOU4xPCEEsTCxO{42PCEQvF2= Ml6wNlUzPzd2NkG=
FaDu MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTiNphkUUN3ME20OU4{QSEEsTCxNU42OCEQvF2= NWrIUJpoOjV{N{e0OlE>
HCV-29T MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFmy[pJKSzVyPUS4MlU4KMLzIEKyMlQ6KM7:TR?= MoroNlUzPzd2NkG=
HL-60 NVjWXVNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHRTWM2OD1zMT6xNEDDuSB2LkS3JO69VQ>? NH3tOYozPTJ5N{S2NS=>
HT-29 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILaRlFKSzVyPUi5MlE3KMLzIEG4Mlg3KM7:TR?= M{HsO|I2Ojd5NE[x
H146 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfPUYJKSzVyPUS5MlbDuTF|LkGg{txO NF;OPJgzPTF{NEK4Ni=>
H187 M33acGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LnUGlEPTB;MUKuO:KyOi55IN88US=> MUeyOVEzPDJ6Mh?=
H128 NV7iR48zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjBb4NqUUN3ME2xNFYvPMLzOT62JO69VQ>? M{DJNFI2OTJ2Mkiy
H69 M4Hyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO1NJVKSzVyPUe2MlnDuTJ5Lkig{txO MnXnNlUyOjR{OEK=
H209 NFXOT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ3OD6xxtE6QS56IN88US=> MWiyOVEzPDJ6Mh?=
DMS153 M1\DS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP6co1KSzVyPUW3MljDuTlwMjFOwG0> NV7yPIlJOjVzMkSyPFI>
H526 M1vhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr3dmRHUUN3ME23MlLDuTFwNzFOwG0> NFmxN|QzPTF{NEK4Ni=>
DMS114 M4nPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvRTWM2OD16NT64xtEyOi56IN88US=> NWjNW5htOjVzMkSyPFI>
DMS53 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTZS|Y3UUN3ME2xOFYvOsLzM{[uOEDPxE1? M4\NVVI2OTJ2Mkiy
HeLa NHzxbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfyVpJvPS16MDFOwG0> NIDhOnpqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M1jzPVI2OTB7M{[w
MCF-7 NXnjW29pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;jOU05OCEQvF2= M2rWbolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NFuzVFEzPTFyOUO2NC=>
MDA-MB-231 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXpOU05OCEQvF2= NEGyPWNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M{PEPVI2OTB7M{[w
CaOV3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWe3NkBp MWTJR|UxRTh4LkGg{txO Ml\RNlUxPjh6NEm=
OVCAR-3 NEHHbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEftN3U4OiCq MXTJR|UxRTF5OT61JO69VQ>? NYHaZopvOjVyNki4OFk>
OVCAR-5 M3z4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXu3NkBp MYrJR|UxRTd3Lkeg{txO NYq0NY0xOjVyNki4OFk>
SKOV-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVq3NkBp MVvJR|UxRTVyNDFOwG0> MXuyOVA3QDh2OR?=
OVCAR-4 M4jjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M131OFczKGh? M1n1UmlEPTB;MkmwMlYh|ryP MXWyOVA3QDh2OR?=
OVCAR-8 MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3TeVdyPzJiaB?= NVPTOHNDUUN3ME22PVAvOiEQvF2= MmDiNlUxPjh6NEm=
MA148 M2LoR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYeyOEBp M{jlTmlEPTB;OEOuOwKBkcLz4pEJNU41KM7:Zz;tcC=> M4HuTFI1QDNzMEmx
A549 NXvKe3RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjUNlQhcA>? M1vyd2lEPTB;N{e2MlDjiIoEsfMAjVEvQSEQvHevcYw> MorqNlQ5OzFyOUG=
MDA-MB-231 M{D5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\tWFI1KGh? NVfTNJRJUUN3ME23OFgvOOLCidMx5qCKOS5zIN88[{9udA>? M16xc|I1QDNzMEmx
NCI-ADR/RES  NUTHT|BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[yWWkzPCCq NYHxeY9{UUN3ME2xO|U{NjEkgJpCtgKBkTRwNDFOwIcwdWx? M4DJNFI1QDNzMEmx
MA148 M2fGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r0clQ5KGh? M1;KcmlEPTB;MkiuNgKBkcLz4pEJNU4xKM7:Zz;tcC=> MYqyOFg{OTB7MR?=
A549 MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknHOFghcA>? MlPTTWM2OD1zMUiuNQKBkcLz4pEJNU4zKM7:Zz;tcC=> NF3K[I4zPDh|MUC5NS=>
MDA-MB-231 NFTCNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWC0PEBp MnfwTWM2OD1zOEOuNQKBkcLz4pEJNU4zKCEQvHevcYw> MVuyOFg{OTB7MR?=
NCI-ADR/RES  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm0fms1QCCq MUHJR|UxRTF7Mz6w5qCKyrIkgJmxMlkh|rypL33s NX\iW5BDOjR6M{GwPVE>
MA148 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn5fpU4PzJiaB?= NYLiSY9zUUN3ME2xN{446oDLwsJihKkyNjJizsznM41t NGnHWmczPDh|MUC5NS=>
A549 M{fIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTFO|IhcA>? MnezTWM2OD14ND6z5qCKyrIkgJmxMlEh|rypL33s M1PwbVI1QDNzMEmx
MDA-MB-231 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWeze|A3PzJiaB?= M{jV[WlEPTB;OUmuOgKBkcLz4pEJNU4yKM7:Zz;tcC=> MV2yOFg{OTB7MR?=
NCI-ADR/RES  Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe1eZY4OiCq NXLTTWg4UUN3ME2zO{416oDLwsJihKkyNjdizsznM41t NIjEeoszPDh|MUC5NS=>
A549 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnPO|IhcA>? MlPSSG1UVw>? MWLJR|UxRTF3Mj60NFkh|ryP M3frSFI1PzJzM{Kz
NCI-H157 M4jJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XWeFczKGh? NIW3N25FVVOR NYfUdpViUUN3ME24PU46PzdizszN M3\jVFI1PzJzM{Kz
PC9 Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojYO|IhcA>? NVfvTmlQT0N3ME23NU43yrF7LkWgxtVO NUHjbYpzOjR4MUi4NFk>
A549  Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\GOnE4OiCq MoDVS2M2OD1zM{dCtVMyNjZiwsXNxsA> NEPTeoUzPDZzOEiwPS=>
PC9 Ml7RRZBweHSxc3nzJGF{e2G7 NWPFXm5bOTByINM1US=> MnvkO|IhcA>? MkjqbY5lfWOnczDhdI9xfG:|aYO= NXPSZXU4OjR4MUi4NFk>
A549  MlzTRZBweHSxc3nzJGF{e2G7 NW\JUWkzOTByINM1US=> NFThZYg4OiCq M1zRc4lv\HWlZYOgZZBweHSxc3nz NUPlV5dTOjR4MUi4NFk>
A549 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnSeIFROjRiaB?= NHvOOmpKSzFyPUGuOFc3KG6P M1q0RlI1Ozl4NEO3
H1299 NGe5SFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:3XVI1KGh? NV7hVWdiUUNzME2wMlQ1OyCwTR?= M{C5[|I1Ozl4NEO3
HCC15 NHXwRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrGNXFSOjRiaB?= NX2zS2dHUUNzME2wMlM1PiCwTR?= NFiyT|AzPDN7NkSzOy=>
H157 M3HOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmyOEBp NUjZe2pqUUNzME2wMlgyKG6P Mmj3NlQ{QTZ2M{e=
A2780 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXueHFmUUN3ME2xOE4x6oDLwsJihKkyNjRizszN NHz3eoczPDJyOU[5Ny=>
A2780cisR NHGzNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTR6LkpihKnDueLCiUOuPUDPxE1? NEDFdnczPDJyOU[5Ny=>
A2780ZD0473R MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\mc5pKSzVyPU[0MlbjiIoEsfMAjVMvOiEQvF2= MmTTNlQzODl4OUO=
SKOV-3 M{\ufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETNe5dKSzVyPUSzMlTjiIoEsfMAjVMvQSEQvF2= NWP5cXN[OjR{MEm2PVM>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
pChK-2 / Chk-2 ; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p38 / p38 / Cleaved PARP / PARP ; 

PubMed: 30049957     


A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋€𢡄�෋€䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄

30049957
Immunofluorescence
γH2AX ; 

PubMed: 24348048     


Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ

24348048
Growth inhibition assay
Cell viability ; 

PubMed: 24348048     


SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay. 

24348048
In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]
- Collapse
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]
- Collapse
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing. 		4.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt
CAS No. 41575-94-4
Storage powder
temperature in solvent (should be freshly prepared each time)
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03968653 Recruiting Drug: Debio 0123|Drug: Carboplatin Advanced Solid Tumors Debiopharm International SA July 30 2019 Phase 1
NCT03723967 Recruiting Drug: Durvalumab with Carboplatin/Paclitaxel Squamous Cell Carcinoma of the Head and Neck Centre Leon Berard May 16 2019 Phase 2
NCT03694834 Suspended Drug: Pembrolizumab|Procedure: Hysterectomy Endometrial Cancer|Uterine Cancer UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp. March 29 2019 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

selleck catalog

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

  • SCR7 New

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.

  • Blasticidin S HCl New

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • YK-4-279 New

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. DMF is recommended, compared with DMSO.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Oxaliplatin

    Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Gemcitabine

    Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

  • Cytarabine

    Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

    Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID